•  
  •  
  •  
  •  

2025-12-12 23:16:22

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • KEC International wins New Orders of Rs. 1,150 crores
  • Emagia Convenes Global Summit to Explore the Next Wave of AI in Enterprise Finance
  • Lemon Tree Hotels signs a new property in Punjab
  • L T Elevator Ltd approves purchase of Commercial Land
  • Hindustan Zinc saves over 1 lakh GJ of energy in FY25; enough to power nearly 19,000 households annually

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Successful completion of USFDA inspection at Vizag facility
  • Caplin Point Laboratories Ltd's injectables facility completes INVIMA audit successfully
  • Apitoria Pharma Pvt Ltd receives 3 observations from USFDA for Unit-V
  • Granules Life Sciences Pvt Ltd facility receives EIR from USFDA
  • Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain
  • Shilpa Medicare Receives Initial Authorization for Rotigotine Transdermal Patch from Europe
  • Shelter Pharma Ltd secures order from Taha Drugs & Chemicals Co. Ltd
  • Granules India Ltd receives official 2025 CDP rating
  • Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg
  • Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%
  • Suven Life Sciences achieved 100% Patient Enrolment Milestone in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder
  • Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial
  • Cipla launches Yurpeak® (tirzepatide) for the treatment of Obesity and Type 2 Diabetes
  • Fermenta Board approves INR 110 Crore Capex at Dahej for Plant-based Vitamin D3, Green Chemistry Enzyme, and Vitamin D3 Derivatives
  • GMP Inspection by Malta Medicines Authority at Alkem's manufacturing facility located at Daman, India
  • Zydus launches biosimilar Denosumab 120 mg SC - protecting bone health in cancer patients
  • Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
  • Caplin Steriles gets USFDA approval for Linezolid Injection, Infusion bags
  • Caplin Steriles granted final approval by USFDA for Acetaminophen Injection, infusion bags
  • Venus Remedies Marks Completion of AMR Licensing Milestones with Final Rs. 11 Crore Payment
  • EDQM issues CEP Certificate for MINOXIDIL to IOL Chemicals & Pharmaceuticals Ltd
  • Senores Pharmaceuticals receives Philippine FDA approval for 10 products
  • Anuh Pharma Ltd granted CEP from EDQM for Sulfadimethoxine

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • KEC International wins New Orders of Rs. 1,150 crores
  • Emagia Convenes Global Summit to Explore the Next Wave of AI in Enterprise Finance
  • Lemon Tree Hotels signs a new property in Punjab
  • L T Elevator Ltd approves purchase of Commercial Land
  • Hindustan Zinc saves over 1 lakh GJ of energy in FY25; enough to power nearly 19,000 households annually


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024